| Evolution of reporting P values in the biomedical literature, 1990-2015 D Chavalarias, JD Wallach, AHT Li, JPA Ioannidis Jama 315 (11), 1141-1148, 2016 | 445 | 2016 |
| Reproducible research practices and transparency across the biomedical literature SA Iqbal, JD Wallach, MJ Khoury, SD Schully, JPA Ioannidis PLoS biology 14 (1), e1002333, 2016 | 329 | 2016 |
| Reproducible research practices, transparency, and open access data in the biomedical literature, 2015–2017 JD Wallach, KW Boyack, JPA Ioannidis PLoS biology 16 (11), e2006930, 2018 | 213 | 2018 |
| Meta-analysis comparing established risk prediction models (EuroSCORE II, STS Score, and ACEF Score) for perioperative mortality during cardiac surgery PG Sullivan, JD Wallach, JPA Ioannidis The American journal of cardiology 118 (10), 1574-1582, 2016 | 154 | 2016 |
| An empirical assessment of transparency and reproducibility-related research practices in the social sciences (2014–2017) TE Hardwicke, JD Wallach, MC Kidwell, T Bendixen, S Crüwell, ... Royal Society Open Science 7 (2), 190806, 2020 | 139 | 2020 |
| Estimating the Prevalence of Transparency and Reproducibility-Related Research Practices in Psychology (2014–2017) TE Hardwicke, RT Thibault, JE Koise, JD Wallach, MC Kidwell, ... Perspectives on Psychological Science, 2021 | 138 | 2021 |
| Evaluation of evidence of statistical support and corroboration of subgroup claims in randomized clinical trials JD Wallach, PG Sullivan, JF Trepanowski, KL Sainani, EW Steyerberg, ... JAMA internal medicine 177 (4), 554-560, 2017 | 132 | 2017 |
| Assessment of transparency indicators across the biomedical literature: How open is open? S Serghiou, DG Contopoulos-Ioannidis, KW Boyack, N Riedel, ... PLoS biology 19 (3), e3001107, 2021 | 95 | 2021 |
| Beyond genomics: understanding exposotypes through metabolomics NJW Rattray, NC Deziel, JD Wallach, SA Khan, V Vasiliou, JPA Ioannidis, ... Human genomics 12, 1-14, 2018 | 91 | 2018 |
| Sex based subgroup differences in randomized controlled trials: empirical evidence from Cochrane meta-analyses JD Wallach, PG Sullivan, JF Trepanowski, EW Steyerberg, JPA Ioannidis bmj 355, 2016 | 79 | 2016 |
| Updating insights into rosiglitazone and cardiovascular risk through shared data: individual patient and summary level meta-analyses JD Wallach, K Wang, AD Zhang, D Cheng, HKG Nardini, H Lin, ... bmj 368, 2020 | 77 | 2020 |
| Postmarket studies required by the US Food and Drug Administration for new drugs and biologics approved between 2009 and 2012: cross sectional analysis JD Wallach, AC Egilman, SS Dhruva, ME McCarthy, JE Miller, S Woloshin, ... bmj 361, 2018 | 67 | 2018 |
| Clinical trial evidence supporting FDA approval of drugs granted breakthrough therapy designation J Puthumana, JD Wallach, JS Ross Jama 320 (3), 301-303, 2018 | 56 | 2018 |
| Adherence to the International Committee of Medical Journal Editors’(ICMJE) prospective registration policy and implications for outcome integrity: a cross-sectional analysis … AD Gopal, JD Wallach, JA Aminawung, G Gonsalves, R Dal-Ré, JE Miller, ... Trials 19, 1-13, 2018 | 52 | 2018 |
| Gabapentin approvals, off-label use, and lessons for postmarketing evaluation efforts JD Wallach, JS Ross Jama 319 (8), 776-778, 2018 | 52 | 2018 |
| The US Food and Drug Administration’s expedited approval programs: Evidentiary standards, regulatory trade-offs, and potential improvements JD Wallach, JS Ross, H Naci Clinical Trials 15 (3), 219-229, 2018 | 49 | 2018 |
| Assessment of preprint policies of top-ranked clinical journals DS Massey, MA Opare, JD Wallach, JS Ross, HM Krumholz JAMA Network Open 3 (7), e2011127-e2011127, 2020 | 43 | 2020 |
| Evaluation of confounding in epidemiologic studies assessing alcohol consumption on the risk of ischemic heart disease: a cross-sectional analysis. PREPRINT (Version 1 … JD Wallach, S Serghiou, L Chu, AC Egilman, V Vasiliou, JS Ross, I JPA https://www.researchsquare.com/article/8e138689-12d5-43fa-87c9-9766d9e11a53, 2019 | 38* | 2019 |
| Medical journal requirements for clinical trial data sharing: Ripe for improvement F Naudet, M Siebert, C Pellen, J Gaba, C Axfors, I Cristea, V Danchev, ... PLoS medicine 18 (10), e1003844, 2021 | 29 | 2021 |
| Real-world cardiovascular outcomes associated with degarelix vs leuprolide for prostate cancer treatment JD Wallach, Y Deng, RG McCoy, SS Dhruva, J Herrin, A Berkowitz, ... JAMA network open 4 (10), e2130587-e2130587, 2021 | 29 | 2021 |
Joseph S. RossYale UniversityVerified email at yale.edu
